Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is focused on the development and commercialization of pharmaceutical products. Its primary focus areas are gastroenterology, ophthalmology and oncology-related disorders. Its product candidates include VTS-270, Lubiprostone (AMITIZA), Unoprostone is opropyl (RESCULA) and CPP-1X/sulindac combination product. VTS-270 is an investigational drug under clinical study for the treatment of Niemann-Pick Disease Type C-1, an ultra-orphan, progressive and fatal disease. AMITIZA is a ClC-2 chloride channel activator, which has been approved for three indications that cover distinct patient types: chronic idiopathic constipation, irritable bowel syndrome with constipation, and opioid-induced constipation. RESCULA is a Big Potassium channel activator used to lower intraocular pressure. CPP-1X/sulindac combination product is meant for the treatment of familial adenomatous polyposis (FAP).
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
SymbolNASDAQ:SCMP
CUSIP86490910
Phone+1-301-9613400
Debt
Debt-to-Equity Ratio7.37
Current Ratio5.11
Quick Ratio4.46
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E Ratio16.07
P/E Growth5.06
Sales & Book Value
Annual Sales$230.06 million
Price / Sales3.69
Cash Flow$2.4096 per share
Price / Cash7.47
Book Value$3.60 per share
Price / Book5.00
Profitability
EPS (Most Recent Fiscal Year)N/A
Net Income$18.48 million
Net Margins16.92%
Return on Equity126.04%
Return on Assets11.04%
Miscellaneous
Employees139
Outstanding Shares47,170,000
Market Cap$839.46
Sucampo Pharmaceuticals (NASDAQ:SCMP) Frequently Asked Questions
What is Sucampo Pharmaceuticals' stock symbol?
Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."
How were Sucampo Pharmaceuticals' earnings last quarter?
Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) posted its quarterly earnings results on Wednesday, November, 1st. The biopharmaceutical company reported $0.27 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.25 by $0.02. The biopharmaceutical company earned $61.27 million during the quarter, compared to analyst estimates of $58.05 million. Sucampo Pharmaceuticals had a net margin of 16.92% and a return on equity of 126.04%. The company's revenue was up 5.9% on a year-over-year basis. During the same period in the prior year, the business posted $0.30 earnings per share. View Sucampo Pharmaceuticals' Earnings History.
What price target have analysts set for SCMP?
8 equities research analysts have issued twelve-month price targets for Sucampo Pharmaceuticals' stock. Their predictions range from $15.00 to $43.00. On average, they expect Sucampo Pharmaceuticals' stock price to reach $22.8750 in the next twelve months. This suggests a possible upside of 27.1% from the stock's current price. View Analyst Ratings for Sucampo Pharmaceuticals.
What is the consensus analysts' recommendation for Sucampo Pharmaceuticals?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Sucampo Pharmaceuticals in the last year. There are currently 6 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
What are Wall Street analysts saying about Sucampo Pharmaceuticals stock?
Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Sucampo’s pending acquisition by Mallinckrodt for $1.2 billion have raised investor concerns that the latter may be underpaying for the company. A sNDA for label expansion of Amitizia in pediatric functional constipation is under review. Also, Sucampo’s collaborations with firms like Takeda and Mylan for Amitiza’s commercialization is a big positive. Moreover, the Vtesse acquisition added a pivotal program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning with few companies trying to market and sell generic version of Amitiza. Moreover, Sucampo discontinued Amitzia’s sprinkle formulation development as it did not meet bioequivalence with capsule formulation. Shares of the company have outperformed the industry. Estimates have remained stable ahead of the Q4 earnings results. The company has a mixed record of earnings surprises in recent quarters." (2/9/2018)
- 2. Maxim Group analysts commented, "Sucampo’s stock has risen sharply in the past few weeks (from ~$10 to $16+) on no new fundamental news. However, a Bloomberg story has been circulating that the company may be entertaining suitors. We have no specific knowledge to confirm this, but do see an undervalued company that is generating free cash flow and has a strong (orphan) pipeline. Our last note (from 11/21) reviewed the R&D Day which focused on two key pipeline products, VTS-270 (Neeman Pick Disease) and CPP-1X/sulindac (Familial Adenomatous Polyposis )." (12/7/2017)
Who are Sucampo Pharmaceuticals' key executives?
Sucampo Pharmaceuticals' management team includes the folowing people:
- Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer (Age 47)
- Peter P. Pfreundschuh CPA, Chief Financial Officer (Age 48)
- Max Donley, Executive Vice President of Global Human Resources, Information Technology and Strategy (Age 48)
- Matthias Alder, Executive Vice President (Age 52)
- Peter A. Kiener Ph.D., Chief Scientific Officer (Age 64)
- Alex Driggs, General Counsel, Corporate Secretary (Age 41)
- Peter Lichtlen M.D., Ph.D., Chief Medical Officer (Age 47)
- John H. Johnson, Lead Independent Director (Age 58)
- Paul R. Edick, Director (Age 62)
- Daniel P. Getman Ph.D., Director (Age 59)
Has Sucampo Pharmaceuticals been receiving favorable news coverage?
News coverage about SCMP stock has trended somewhat positive recently, Accern Sentiment reports. The research group identifies negative and positive news coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sucampo Pharmaceuticals earned a daily sentiment score of 0.12 on Accern's scale. They also assigned media headlines about the biopharmaceutical company an impact score of 45.57 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.
How do I buy shares of Sucampo Pharmaceuticals?
Shares of SCMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Sucampo Pharmaceuticals' stock price today?
One share of SCMP stock can currently be purchased for approximately $18.00.
How big of a company is Sucampo Pharmaceuticals?
Sucampo Pharmaceuticals has a market capitalization of $839.46 million and generates $230.06 million in revenue each year. Sucampo Pharmaceuticals employs 139 workers across the globe.
How can I contact Sucampo Pharmaceuticals?
Sucampo Pharmaceuticals' mailing address is 805 King Farm Blvd Ste 550, ROCKVILLE, MD 20850-6162, United States. The biopharmaceutical company can be reached via phone at +1-301-9613400 or via email at [email protected]
MarketBeat Community Rating for Sucampo Pharmaceuticals (NASDAQ SCMP)
MarketBeat's community ratings are surveys of what our community members think about Sucampo Pharmaceuticals and other stocks. Vote "Outperform" if you believe SCMP will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SCMP will underperform the S&P 500 over the long term. You may vote once every thirty days.
